...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer >A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients.
【24h】

A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients.

机译：镁补充剂减少乳腺癌患者更年期潮热的一项II期试验性试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: We tested if magnesium would diminish bothersome hot flashes in breast cancer patients. METHODS: Breast cancer patients with at least 14 hot flashes a week received magnesium oxide 400 mg for 4 weeks, escalating to 800 mg if needed. Hot flash score (frequency x severity) at baseline was compared to the end of treatment. RESULTS: Of 29 who enrolled, 25 women completed treatment. The average age was 53.5 years; six African American, the rest Caucasian; eight were on tamoxifen, nine were on aromatase inhibitors, and 14 were on anti-depressants. Seventeen patients escalated the magnesium dose. Hot flash frequency/week was reduced from 52.2 (standard error (SE), 13.7) to 27.7 (SE, 5.7), a 41.4% reduction, p = 0.02, two-sided paired t test. Hot flash score was reduced from 109.8 (SE, 40.9) to 47.8 (SE, 13.8), a 50.4% reduction, p = 0.04. Of 25 patients, 14 (56%) had a >50% reduction in hot flash score, and 19 (76%) had a >25% reduction. Fatigue, sweating, and distress were all significantly reduced. Side effects were minor: two women stopped the drug including one each with headache and nausea, and two women had grade 1 diarrhea. Compliance was excellent, and many patients continued treatment after the trial. CONCLUSIONS: Oral magnesium appears to have helped more than half of the patients and was well tolerated. Side effects and cost (Dollars 0.02/tablet) were minimal. A randomized placebo-controlled trial is planned.
机译：背景：我们测试了镁是否可以减少乳腺癌患者的烦躁潮热。方法：每周至少出现14次潮热的乳腺癌患者接受400毫克氧化镁治疗4周，如果需要，可增加至800毫克。将基线时的潮热分数（频率x严重程度）与治疗结束时进行比较。结果：在29名患者中，有25名妇女完成了治疗。平均年龄为53.5岁;六位非洲裔美国人，其余高加索人;他莫昔芬使用8种，芳香酶抑制剂使用9种，抗抑郁药使用14种。 17名患者增加了镁的剂量。双面配对t检验将每周热闪光频率从52.2（标准误差（SE），13.7）降低至27.7（SE，5.7），降低了41.4％，p = 0.02。热闪分数从109.8（SE，40.9）降低到47.8（SE，13.8），降低了50.4％，p = 0.04。在25例患者中，有14例（56％）的热潮红分数降低了> 50％，而19例（76％）的热闪分数降低了> 25％。疲劳，出汗和痛苦都明显减少。副作用很小：两名妇女停用了该药，包括头痛和恶心的一名，两名妇女患有1级腹泻。依从性非常好，许多患者在试验后继续治疗。结论：口服镁似乎对一半以上的患者有帮助，并且耐受性良好。副作用和成本（0.02美元/片）最低。计划进行一项随机安慰剂对照试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号